MC-Sq-Cit-PAB-Gefitinib |
| Katalog-Nr.GC36564 |
MC-Sq-Cit-PAB-Gefitinib ist ein Wirkstoff-Linker-Konjugat fÜr ADC mit starker AntitumoraktivitÄt unter Verwendung von Gefitinib (einem EGFR-Tyrosinkinase-Inhibitor), verbunden Über den ADC-Linker MC-Sq-Cit-PAB.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1941168-63-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MC-Sq-Cit-PAB-Gefitinib has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Sq-Cit-PAB-Gefitinib is used for the antibody-drug conjugates (ADC) to treat various diseases or disorders, e.g. characterized by the overexpression of a tumor antigen[1,2].
[1]. FLYGARE, John A, et al. Quaternary amine compounds and antibody-drug conjugates thereof. WO2016090050A1. [2]. Staben LR, et al. Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates. Nat Chem. 2016 Dec;8(12):1112-1119.
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *